Find a Parkview Health Clinical Trial
5 results found
Current Studies
Primary To compare disease-free survival (DFS) as assessed by investigator for participants treated with belzutifan plus pembrolizumab versus those receiving placebo plus pembrolizumab Hypothesis (1): Belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to...
- Objective: To compare pathologic complete response (pCR) rates obtained in Arm A (preoperative pembrolizumab and RC+PLND) and Arm B (RC+PLND), based on central pathologic review, evaluated in participants whose tumors express PD-L1 CPS ≥10 and all participants, irrespective of CPS score. -...
Primary Objectives - Objective: To compare the HIF triplet to the doublet with respect to PFS per RECIST 1.1 as assessed by BICR. - Hypothesis (H1): The HIF triplet is superior to the doublet with respect to PFS per RECIST 1.1 by BICR in advanced ccRCC patients with IMDC intermediate/poor risk. -...
Primary Objective: -To compare MK- 6482+lenvatinib to cabozantinib with respect to PFS per Response Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). -Hypothesis (H1): MK-6482+lenvatinib is superior to cabozantinib with respect to PFS per RECIST 1.1 by...
PRIMARY OBJECTIVES: I. To assess the benefit of docetaxel as measured by improvement in freedom from progression (phase II) and subsequently metastasis free survival (phase III) when given in combination with radiation and androgen deprivation in treatment of high risk prostate cancer post-radical...